The Extraordinary Lee Whyberd A Healer for Our Times
April 8, 2022Nothing about 52-year-old international powerhouse of healing Lee Whyberd is ordinary, not least his capacity for...
When most of us think about venturing to other planets, the image that springs to mind is a gleaming rocket blazing into the night sky. But ask scientists who study the human body in space, and you’ll hear a very different story. The real battle for interstellar exploration may not be fought in steel and fire – but in flesh, blood, and biology.
The past decade has seen astonishing in terms of technology and progress towards life beyond earth. Launch costs are tumbling, and companies once dismissed as dreamers are now genuine players in the space economy.
Entrepreneurs such as Elon Musk have accelerated the timetable, making humanity’s migration beyond Earth feel like a question of “when” rather than “if.” Yet the greatest hurdle may not be how far our spacecraft can fly, but how long our bodies can endure. In orbit, astronauts rapidly lose bone density, muscle mass, and even heart strength because the absence of gravity tricks the body into idleness.
Vision blurs as bodily fluids drift upward, faces puff up, and radiation is relentless – bombarding travellers with invisible particles that can damage DNA and heighten the risk of cancer. Cell death in space is a largely unspoken challenge.
This is where a British biotech company, LinkGevity, enters the picture. Founded by sisters Carina Kern and Serena Kern-Libera, the firm is tackling ageing itself – a problem magnified in space but equally urgent on Earth. Their work, underpinned by Blueprint Theory, as detailed here https://www.preprints.org/manuscript/202310.1387/v4 , is focused on slowing or even reshaping cellular decline. The company has already won interest from NASA’s Space Health program, that increasingly recognise biology as mission-critical technology. “People think of space exploration as an engineering challenge,” says Dr Carina Kern, LinkGevity’s chief executive. “But the truth is, biology could make or break the future of spaceflight. Rockets might get us there, but the human body must be able to survive the journey.”
The company’s scientists are experimenting with drugs designed to influence necrosis, the process by which cells die and tissues deteriorate. In practical terms, these treatments could not only help astronauts maintain healthy organs in space but also deliver breakthroughs for millions coping with age-related diseases here on Earth – from cardiovascular failure to kidney decline.
For all the talk of Mars colonies and lunar bases, the real story may be that humanity’s push into space forces us to confront our own biological fragility. The stresses of cosmic radiation, isolation, and altered gravity make ageing-like conditions visible in extreme close-up. And in that magnified view lies opportunity: the chan
ce to develop new medicines that extend not just our journeys through the stars, but also our healthy years on Earth. Dr Carina Kern’s revelatory research, see Necrosis Nature Oncogene: https://doi.org/10.1038/s41388-025-03431-y, has made major ripples in the scientific community. With a pipeline of new drug candidates due to be unveiled in the coming months, LinkGevity represents a striking fusion of two great human quests: to outpace the march of time, and to step boldly into the unknown. The road to the stars, it seems, might just run through the laboratory.
Other Luxury Stories
The Piano Works start the party early with Saturday Brunch!
February 28, 2017Recently described as ‘the hottest club in London’ by The Express and ranked as one of the top 50 bars in the capital by...
Next Generation Greeting Cards Break Tradition this Christmas
November 25, 2017Start-up specialist Ben Nolan, from London, is the entrepreneur behind Choosey – an online card retailer and...